Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:BLBD NASDAQ:CRSP NASDAQ:NTLA NASDAQ:NVDA NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.84+11.1%$28.46$15.60▼$36.44$3.38B2.252.04 million shs4.39 million shsBLBDBlue Bird$71.95-0.7%$64.32$38.67▼$81.51$2.28B1.37445,970 shs294,920 shsCRSPCRISPR Therapeutics$56.95+9.4%$51.73$37.02▼$78.48$5.49B1.741.86 million shs3.30 million shsNTLAIntellia Therapeutics$14.75+13.3%$13.56$7.31▼$28.25$2.06B1.925.48 million shs9.59 million shsNVDANVIDIA$218.66+1.8%$201.97$138.83▼$236.54$5.29T2.22172.17 million shs167.92 million shsVRTXVertex Pharmaceuticals$441.74+3.1%$437.63$362.50▼$507.92$112.11B0.31.38 million shs1.36 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+2.04%-7.34%-3.79%+15.79%+75.06%BLBDBlue Bird+0.12%+2.20%+15.21%+28.26%+87.01%CRSPCRISPR Therapeutics+0.12%-2.71%+0.87%-9.16%+36.91%NTLAIntellia Therapeutics-0.84%-3.13%-1.81%-0.99%+69.31%NVDANVIDIA-3.62%+1.01%+8.21%+17.14%+52.07%VRTXVertex Pharmaceuticals+0.76%-2.03%+1.04%-7.05%-4.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.84+11.1%$28.46$15.60▼$36.44$3.38B2.252.04 million shs4.39 million shsBLBDBlue Bird$71.95-0.7%$64.32$38.67▼$81.51$2.28B1.37445,970 shs294,920 shsCRSPCRISPR Therapeutics$56.95+9.4%$51.73$37.02▼$78.48$5.49B1.741.86 million shs3.30 million shsNTLAIntellia Therapeutics$14.75+13.3%$13.56$7.31▼$28.25$2.06B1.925.48 million shs9.59 million shsNVDANVIDIA$218.66+1.8%$201.97$138.83▼$236.54$5.29T2.22172.17 million shs167.92 million shsVRTXVertex Pharmaceuticals$441.74+3.1%$437.63$362.50▼$507.92$112.11B0.31.38 million shs1.36 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+2.04%-7.34%-3.79%+15.79%+75.06%BLBDBlue Bird+0.12%+2.20%+15.21%+28.26%+87.01%CRSPCRISPR Therapeutics+0.12%-2.71%+0.87%-9.16%+36.91%NTLAIntellia Therapeutics-0.84%-3.13%-1.81%-0.99%+69.31%NVDANVIDIA-3.62%+1.01%+8.21%+17.14%+52.07%VRTXVertex Pharmaceuticals+0.76%-2.03%+1.04%-7.05%-4.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.71Moderate Buy$46.8342.61% UpsideBLBDBlue Bird 2.63Moderate Buy$77.808.13% UpsideCRSPCRISPR Therapeutics 2.53Moderate Buy$65.4714.96% UpsideNTLAIntellia Therapeutics 2.35Hold$20.2537.29% UpsideNVDANVIDIA 3.00Buy$305.3839.66% UpsideVRTXVertex Pharmaceuticals 2.88Moderate Buy$555.9125.85% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026NVDANVIDIA William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026NVDANVIDIA Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$270.006/1/2026BLBDBlue Bird DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$86.006/1/2026NVDANVIDIA DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$300.005/27/2026NVDANVIDIA Tigress FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$360.00 ➝ $425.005/27/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026NVDANVIDIA Tigress FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$360.00 ➝ $425.005/27/2026VRTXVertex Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$542.005/26/2026NVDANVIDIA Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$280.00 ➝ $300.005/22/2026NVDANVIDIA Citic SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$242.00 ➝ $315.005/22/2026NVDANVIDIA Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $255.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M24.18N/AN/A$12.20 per share2.69BLBDBlue Bird$1.48B1.54$4.68 per share15.39$8.06 per share8.93CRSPCRISPR Therapeutics$3.51M1,564.91N/AN/A$20.17 per share2.82NTLAIntellia Therapeutics$67.67M30.45N/AN/A$5.80 per share2.54NVDANVIDIA$215.94B24.51$4.64 per share47.17$8.08 per share27.06VRTXVertex Pharmaceuticals$12.00B9.34$18.27 per share24.18$73.57 per share6.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)BLBDBlue Bird$127.72M$4.0717.6815.211.018.91%53.68%22.19%8/5/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)NVDANVIDIA$120.07B$6.5333.4920.100.5462.97%96.94%72.16%N/AVRTXVertex Pharmaceuticals$3.95B$16.8626.2023.321.8235.51%23.86%17.13%8/3/2026 (Estimated)Latest CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2027NVDANVIDIA$1.76$1.87+$0.11$2.39$78.42 billion$81.62 billion5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/6/2026Q2 2026BLBDBlue Bird$0.8770$1.00+$0.1230$0.90$335.23 million$352.64 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ABLBDBlue BirdN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVDANVIDIA$0.040.02%+14.87%0.61%1 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2026NVDANVIDIAquarterly$0.250.46%6/4/20266/4/20266/26/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99BLBDBlue Bird0.281.831.27CRSPCRISPR Therapeutics0.3217.9717.96NTLAIntellia TherapeuticsN/A6.106.10NVDANVIDIA0.043.442.85VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%BLBDBlue Bird93.59%CRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%NVDANVIDIA65.27%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%BLBDBlue Bird1.10%CRSPCRISPR Therapeutics4.30%NTLAIntellia Therapeutics3.10%NVDANVIDIA3.94%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableBLBDBlue Bird2,01231.65 million31.30 millionOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableNTLAIntellia Therapeutics600139.72 million135.39 millionOptionableNVDANVIDIA42,00024.20 billion23.25 billionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableCRSP, VRTX, NTLA, BEAM, BLBD, and NVDA HeadlinesRecent News About These CompaniesWhy Is Jazz (JAZZ) Up 1% Since Last Earnings Report?3 hours ago | finance.yahoo.comVertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Mcrae Capital Management Inc.June 4 at 6:57 AM | marketbeat.comCIBC Asset Management Inc Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJune 4 at 4:23 AM | marketbeat.comBowen Hanes & Co. Inc. Purchases 9,070 Shares of Vertex Pharmaceuticals Incorporated $VRTXJune 4 at 3:29 AM | marketbeat.comBank of New York Mellon Corp Sells 41,579 Shares of Vertex Pharmaceuticals Incorporated $VRTXJune 4 at 3:28 AM | marketbeat.comVertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10June 3 at 7:10 PM | finance.yahoo.comVertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?June 3 at 2:09 PM | finance.yahoo.comVertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?June 3 at 12:36 PM | zacks.comShepherd Street Advisors LLC Buys Shares of 2,995 Vertex Pharmaceuticals Incorporated $VRTXJune 3 at 6:44 AM | marketbeat.comVertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?June 3 at 1:51 AM | finance.yahoo.comIs Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation?June 2 at 7:26 PM | finance.yahoo.comAnalyst Report: Vertex Pharmaceuticals IncJune 2 at 3:11 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated: Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX, a First-in-Class Non-Opioid Treatment for Adults ...June 2 at 2:25 PM | finanznachrichten.deShould FDA’s IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticals’ (VRTX) Investment Narrative?June 2 at 2:25 PM | finance.yahoo.comGot $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely MispricingJune 2 at 12:11 PM | 247wallst.comFDA Accepts Vertex's BLA for Povetacicept in IgA NephropathyJune 2 at 12:10 PM | zacks.comGot $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely MispricingJune 2 at 12:02 PM | 247wallst.comNatixis Advisors LLC Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJune 2 at 7:25 AM | marketbeat.comGW Henssler & Associates Ltd. Trims Stake in Vertex Pharmaceuticals Incorporated $VRTXJune 2 at 6:45 AM | marketbeat.comVertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?June 1 at 2:10 PM | barchart.comVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA NephropathyJune 1 at 12:09 PM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesA Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026The Smarter Way to Invest in AI Without Taking Extreme RiskBy Chris Markoch | May 31, 2026NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingBy Thomas Hughes | May 21, 2026Aggressive Insider Buying Signals Opportunity in 3 Risky StocksBy Thomas Hughes | June 2, 20265 Stocks Positioned to Benefit From the AI Inference BoomBy Ryan Hasson | May 11, 2026CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA Company DescriptionsBeam Therapeutics NASDAQ:BEAM$32.84 +3.29 (+11.13%) Closing price 04:00 PM EasternExtended Trading$32.30 -0.55 (-1.66%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Blue Bird NASDAQ:BLBD$71.95 -0.48 (-0.66%) Closing price 04:00 PM EasternExtended Trading$71.85 -0.10 (-0.14%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States, Canada, and internationally. The company operates through two segments, Bus and Parts. It offers Type C, Type D, and specialty buses; and alternative power options through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. The company also sells replacement bus parts; and provides financing services and extended warranties related to its products. Blue Bird Corporation sells its products through drop ship and a network of dealers, as well as directly to fleet operators, the United States government, and state governments; independent service centers; and maintains a parts distribution center. Blue Bird Corporation was founded in 1927 and is headquartered in Macon, Georgia.CRISPR Therapeutics NASDAQ:CRSP$56.95 +4.87 (+9.35%) Closing price 04:00 PM EasternExtended Trading$56.09 -0.86 (-1.50%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$14.75 +1.73 (+13.29%) Closing price 04:00 PM EasternExtended Trading$14.81 +0.06 (+0.43%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.NVIDIA NASDAQ:NVDA$218.66 +3.91 (+1.82%) Closing price 04:00 PM EasternExtended Trading$217.40 -1.26 (-0.58%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.Vertex Pharmaceuticals NASDAQ:VRTX$441.74 +13.40 (+3.13%) Closing price 04:00 PM EasternExtended Trading$445.08 +3.34 (+0.76%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
